To our knowledge, this is a preliminary experience to demonstrate the distribution between CA9 SNP and EGFR phenotype that could affect the clinicopathologic characteristics of lung adenocarcinoma, which may lower the risk of disease deterioration [49,50]. The gene discussed is CA9; the disease is lung adenocarcinoma.